Conor Hayes

Title: Conor Hayes: Innovator in T Cell Receptor Technology

Introduction

Conor Hayes is a prominent inventor based in Abingdon, GB. He has made significant contributions to the field of immunotherapy, particularly through his work on T cell receptors (TCRs). With a total of 2 patents, Hayes is recognized for his innovative approaches to cancer treatment.

Latest Patents

Hayes' latest patents focus on T cell receptors that bind specific peptides derived from cancer antigens. One of his inventions relates to TCRs that bind the HLA-A*02 restricted peptide GVYDGREHTV, which is derived from the germline cancer antigen MAGE A4. These TCRs may include non-natural mutations within the alpha and/or beta variable domains, making them particularly suitable for use as novel immunotherapeutic reagents for treating malignant diseases. Another patent involves TCRs that bind the HLA-A*02 restricted peptide GLYDGMEHL, derived from the MAGE-A10 protein. These TCRs demonstrate excellent specificity profiles for this MAGE epitope and include nucleic acids encoding the TCRs, engineered cells, and pharmaceutical compositions.

Career Highlights

Throughout his career, Conor Hayes has worked with notable companies in the biotechnology sector, including Immunocore Limited and Adaptimmune Limited. His work has significantly advanced the understanding and application of T cell receptors in cancer therapy.

Collaborations

Hayes has collaborated with several professionals in his field, including Linda Hibbert and Nathaniel Ross Liddy. These collaborations have contributed to the development and refinement of his innovative TCR technologies.

Conclusion

Conor Hayes is a key figure in the advancement of T cell receptor technology, with a focus on developing novel immunotherapeutic approaches for cancer treatment. His contributions are paving the way for future innovations in the field of immunotherapy.